📚 Overview: Two Medication Classes for ADHD
ADHD medications fall into two main categories: stimulants and non-stimulants. Understanding the differences is crucial for choosing the right treatment.
Why This Matters
- First-line treatment matters: Starting with the most effective medication class increases likelihood of symptom control
- Not everyone can take stimulants: Cardiac issues, substance use history, or severe anxiety may make stimulants inappropriate
- Side effects differ significantly: What you can tolerate matters as much as what works
- Coverage needs vary: Some patients need 24-hour symptom control vs focused 8-12 hour coverage
- Combination therapy is common: Many patients ultimately use both classes together
⚡ Stimulant Medications: The First-Line Standard
Why Stimulants Are First-Line
All major ADHD treatment guidelines (American Academy of Pediatrics, American Academy of Child & Adolescent Psychiatry) recommend stimulants as first-line pharmacotherapy because:
- Highest efficacy: 70-80% response rate (vs 50-60% for non-stimulants)
- Largest effect sizes: d = 0.9-1.0 (considered "large" in research)
- Immediate onset: You know within days if it's working
- Decades of safety data: Used since 1937 (methylphenidate) and 1960s (amphetamines)
- Flexibility: Can adjust dose and timing easily
Two Types of Stimulants
1. Methylphenidate-Based Stimulants
How they work: Block reuptake of dopamine and norepinephrine in synaptic cleft
Medications:
- Short-acting (3-4 hours): Ritalin, Focalin, Methylin
- Intermediate (6-8 hours): Ritalin LA, Metadate CD
- Long-acting (10-12 hours): Concerta, Focalin XR, Daytrana patch, Jornay PM
Advantages: Shorter half-life (may have less impact on sleep/appetite), less cardiovascular effect than amphetamines
Read: Concerta vs Ritalin Comparison →
2. Amphetamine-Based Stimulants
How they work: Block reuptake AND promote release of dopamine/norepinephrine
Medications:
- Short-acting (4-6 hours): Adderall IR, Dexedrine, ProCentra
- Long-acting (10-14 hours): Adderall XR, Vyvanse, Dexedrine Spansule, Mydayis
Advantages: Longer duration, may be more effective for some patients, smoother extended-release profiles (especially Vyvanse)
Read: Adderall vs Vyvanse Comparison →
Stimulant Pros & Cons
✅ Advantages
- Highest efficacy (70-80% response rate)
- Immediate effect (30-120 minutes)
- Large effect sizes in research
- Can take as needed (medication holidays possible)
- Flexible dosing (multiple formulations)
- Low cost (generics available)
- Well-studied (80+ years of use)
- Works for all ADHD subtypes
❌ Disadvantages
- Controlled substances (Schedule II)
- Abuse potential (diversion risk)
- Appetite suppression (weight loss concern)
- Insomnia common
- Cardiovascular effects (↑ HR, ↑ BP)
- Can worsen anxiety/tics in some patients
- Rebound symptoms when wearing off
- Tolerance may develop
🔷 Non-Stimulant Medications: Alternative Options
Non-stimulants are FDA-approved for ADHD but typically used as second-line treatment (after stimulants) or first-line in specific situations (see "When to Use Non-Stimulants" section).
Three Types of Non-Stimulants
1. Selective Norepinephrine Reuptake Inhibitor (NRI)
Medication: Strattera (atomoxetine) - first non-stimulant FDA-approved for ADHD (2002)
How it works: Selectively blocks reuptake of norepinephrine in prefrontal cortex, improving attention and impulse control
Key Features:
- Dosing: Once or twice daily, can take with/without food
- Time to effect: 4-6 weeks for full benefit (gradual build-up)
- Duration: 24-hour coverage
- Response rate: ~50-60%
- Effect size: d = 0.7 (medium)
Best for:
- Patients with comorbid anxiety (doesn't worsen anxiety like stimulants can)
- Substance use history (no abuse potential)
- Patients who need 24-hour coverage including evenings
- Tics or Tourette's (doesn't worsen tics)
Side effects: Nausea (first 1-2 weeks), dry mouth, decreased appetite, fatigue, sexual dysfunction (adults), rare liver toxicity (black box warning)
Contraindications: MAOIs, narrow-angle glaucoma, severe cardiac disease
2. Alpha-2 Adrenergic Agonists
Medications: Intuniv (guanfacine XR) and Kapvay (clonidine XR)
How they work: Stimulate alpha-2A receptors in prefrontal cortex, improving working memory, attention, and impulse control
Key Features:
- Dosing: Once daily (must take consistently - cannot miss doses)
- Time to effect: 2-4 weeks
- Duration: 24-hour coverage
- Response rate: ~50-60%
- Effect size: d = 0.6-0.7 (medium)
Best for:
- Children with hyperactivity/impulsivity > inattention
- Tics or Tourette's syndrome (can improve tics)
- Sleep problems (sedating - helpful for insomnia)
- Aggression or oppositional behavior
- Combination with stimulants (commonly used together)
Side effects: Sedation (common, especially first 2-3 weeks), low blood pressure, dizziness, dry mouth, constipation, rebound hypertension if stopped abruptly
Important: Cannot stop abruptly - must taper slowly to avoid rebound hypertension
3. Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
Medication: Qelbree (viloxazine ER) - newest non-stimulant, FDA-approved 2021
How it works: Blocks reuptake of norepinephrine and (to lesser extent) dopamine, also modulates serotonin
Key Features:
- Dosing: Once daily in morning, with/without food
- Time to effect: 2-4 weeks
- Duration: 24-hour coverage
- Response rate: ~50-60%
- Schedule: Schedule V (very low abuse potential, but still controlled)
Best for:
- Patients who failed Strattera
- Comorbid depression (may have mood benefits)
- Patients wanting non-stimulant without sedation (less sedating than Intuniv)
Side effects: Somnolence (common), decreased appetite, fatigue, nausea, headache. Black box warning for suicidal ideation in children/adolescents (monitor closely first 2 months)
Note: Very expensive (~$400-500/month), no generic until 2030s
Non-Stimulant Pros & Cons
✅ Advantages
- No abuse potential (except Qelbree - minimal)
- 24-hour coverage (including evenings)
- Less appetite suppression
- Can help comorbid anxiety (Strattera, Intuniv)
- Can improve tics (Intuniv, Kapvay)
- No cardiovascular concerns (Intuniv may lower BP)
- Less insomnia (Intuniv actually helps sleep)
- Not controlled substances (easier prescribing)
❌ Disadvantages
- Lower efficacy (50-60% vs 70-80%)
- Delayed onset (2-6 weeks vs immediate)
- Must take daily (cannot skip or take as needed)
- Sedation common (Intuniv, Kapvay)
- More GI side effects (nausea with Strattera/Qelbree)
- Cannot stop abruptly (taper needed for Intuniv/Kapvay)
- Higher cost (Qelbree very expensive)
- More drug interactions
📈 Head-to-Head Efficacy: What the Research Shows
Meta-Analyses Comparing Stimulants vs Non-Stimulants
Multiple large meta-analyses consistently show stimulants are more effective than non-stimulants for ADHD:
| Study |
Findings |
Cortese et al. (2018)
Lancet Psychiatry |
• Network meta-analysis of 133 RCTs, 10,068 children/adolescents
• Methylphenidate most effective (effect size: 0.78)
• Amphetamines second (effect size: 0.79)
• Non-stimulants lower: Atomoxetine (0.56), Guanfacine (0.63)
|
Faraone & Buitelaar (2010)
Neuropsychopharmacology |
• Stimulants: effect size d = 0.9-1.0 (large)
• Atomoxetine: effect size d = 0.7 (medium)
• Stimulants ~30% more effective than non-stimulants
|
Cunill et al. (2016)
European Psychiatry |
• Atomoxetine efficacy in adults: effect size 0.45
• Significantly lower than stimulants (d = 0.8-1.0)
• But atomoxetine better tolerated (fewer dropouts)
|
Response Rates in Clinical Practice
- Stimulants: 70-80% of patients show clinically significant response
- Non-stimulants: 50-60% of patients show clinically significant response
- Important: Some patients who don't respond to stimulants DO respond to non-stimulants (about 25-30%)
💊 Clinical Pearl: In my
JAMA 2019 study, we found that
optimizing first-line ADHD medications (stimulants primarily) is critical before considering other medication classes. Many patients were receiving antipsychotics for ADHD without adequate stimulant trials - a practice not supported by evidence.
🔄 ADHD Medication Treatment Algorithm
This algorithm reflects evidence-based guidelines from AAP, AACAP, and clinical practice:
STEP 1: First-Line Treatment
→ Stimulant Medication (methylphenidate OR amphetamine)
Start low, titrate to optimal dose based on response and side effects
STEP 2: If Inadequate Response to First Stimulant
→ Switch to Other Stimulant Class
Example: If methylphenidate didn't work, try amphetamine (or vice versa)
60-80% of non-responders to one stimulant will respond to the other class
STEP 3: If Both Stimulant Classes Inadequate
Options:
A) Non-stimulant monotherapy (Strattera, Intuniv, or Qelbree)
B) Combination therapy (Stimulant + Non-stimulant)
Combination often more effective than either alone
STEP 4: If Non-Stimulants Alone Inadequate
→ Combination Therapy
Common combinations: Stimulant + Intuniv, Stimulant + Strattera
STEP 5: Refractory ADHD
→ Consider:
• Re-evaluate diagnosis (is it really ADHD?)
• Treat comorbidities (anxiety, depression, sleep disorders)
• Augmentation strategies (bupropion, modafinil, others)
• Intensive behavioral interventions
Refer to ADHD specialist if not improving
Special Considerations That Change the Algorithm
Start with Non-Stimulants First-Line If:
- ✅ Active substance use disorder or high diversion risk
- ✅ Cardiac concerns (significant arrhythmias, recent MI, severe hypertension)
- ✅ Severe tics or Tourette's worsened by stimulants
- ✅ Severe anxiety exacerbated by stimulants despite adequate anxiety treatment
- ✅ Patient/family preference for non-controlled substance
🎯 When to Use Non-Stimulants: Clinical Scenarios
Scenario 1: Substance Use History
Clinical Picture: 24-year-old with ADHD and past cocaine use disorder, now 2 years sober
Recommendation: Start with Strattera or Qelbree
Rationale: No abuse potential, cannot be diverted. If inadequate response, can cautiously try Vyvanse (lowest abuse potential stimulant due to prodrug design)
Scenario 2: Comorbid Severe Anxiety
Clinical Picture: 16-year-old with ADHD and GAD, stimulant trial worsened anxiety significantly
Recommendation: Strattera or Intuniv
Rationale: Both can improve anxiety while treating ADHD. Intuniv particularly good if sleep problems also present
Scenario 3: Tics or Tourette's Syndrome
Clinical Picture: 10-year-old with ADHD and motor/vocal tics worsened by methylphenidate
Recommendation: Intuniv or Kapvay (first choice), or Strattera
Rationale: Alpha-2 agonists can actually improve tics while treating ADHD. Treats both conditions
Scenario 4: Need for Evening Coverage
Clinical Picture: College student needs ADHD symptom control through evening study sessions (9pm-midnight)
Recommendation: Combination: Long-acting stimulant + Strattera
Rationale: Strattera provides 24-hour baseline coverage. Stimulant for peak daytime effect. Avoids late-day stimulant dose that disrupts sleep
Scenario 5: Cardiac Concerns
Clinical Picture: 45-year-old with ADHD, hypertension (140/90), and family history of early MI
Recommendation: Strattera or Intuniv (if BP remains elevated)
Rationale: Strattera has minimal cardiovascular effects. Intuniv can actually lower blood pressure. Avoid stimulants or use with cardiology clearance and close monitoring
Scenario 6: Severe Appetite Suppression/Weight Loss
Clinical Picture: 8-year-old on Vyvanse, lost 12 lbs (10% body weight) over 4 months despite dietary interventions
Recommendation: Switch to Intuniv or Strattera
Rationale: Non-stimulants have less appetite suppression. Can also consider stimulant "drug holidays" on weekends, but non-stimulant switch often preferable
Scenario 7: Refractory ADHD Despite Stimulant Optimization
Clinical Picture: Adult tried methylphenidate (multiple formulations) and amphetamines (multiple formulations) at adequate doses - partial response only
Recommendation: Add Strattera or Intuniv to stimulant (combination therapy)
Rationale: Combination often more effective than either alone. Targets different neurotransmitter systems
💊 Combination Therapy: Using Both Together
Many patients ultimately benefit from combining stimulant + non-stimulant medications:
Common Effective Combinations
- Stimulant + Intuniv/Kapvay: Most common combination
- Stimulant for core ADHD symptoms during the day
- Alpha-2 agonist for evening coverage, sleep, and impulse control
- Particularly effective for hyperactive/impulsive children
- Stimulant + Strattera: For all-day coverage
- Strattera provides baseline 24-hour symptom control
- Stimulant adds peak effect during work/school hours
- Helpful when stimulant alone wears off too early
Research on Combination Therapy
- Wilens et al. (2005): Atomoxetine + stimulant superior to either monotherapy in adults
- Sallee et al. (2009): Guanfacine XR + stimulant more effective than stimulant alone in children
- Meta-analysis (Cunill et al., 2016): Combination therapy effect size: d = 0.9 (approaching stimulant monotherapy)
💊 Clinical Pearl: I often use combination therapy in patients with ADHD + significant emotional dysregulation. The stimulant improves focus/attention, while Intuniv helps with impulse control and emotional reactivity. It's particularly effective in adolescents.
❓ Frequently Asked Questions
Should I try stimulants or non-stimulants first?
Stimulants first (unless contraindicated). They're more effective (70-80% vs 50-60% response rates), work immediately, and have the most evidence. Start with non-stimulants if you have: substance use history, cardiac concerns, severe anxiety, or tics worsened by stimulants.
If stimulants don't work, will non-stimulants?
Possibly. About 25-30% of stimulant non-responders will respond to non-stimulants. They work through different mechanisms, so failure of one doesn't predict failure of the other.
Can I take stimulants and non-stimulants together?
Yes, very commonly. Combination therapy (stimulant + non-stimulant) is well-studied and often more effective than either alone. Common combinations: stimulant + Intuniv, or stimulant + Strattera.
Are non-stimulants safer than stimulants?
Different safety profiles, not necessarily "safer." Non-stimulants avoid: appetite suppression, insomnia, cardiovascular effects, abuse potential. But they have their own risks: sedation, nausea, rebound hypertension (alpha-2 agonists), liver toxicity (Strattera - rare), suicidal ideation (Qelbree - monitored).
Why don't doctors start with non-stimulants if they have fewer side effects?
Efficacy trumps side effects in first-line choice. Untreated ADHD has serious consequences (academic failure, job loss, accidents, relationship problems). Stimulants give the best chance of symptom control. We use non-stimulants when stimulants aren't appropriate or didn't work.
How long should I try a non-stimulant before deciding it doesn't work?
At least 4-6 weeks at therapeutic dose. Unlike stimulants (which work immediately), non-stimulants take 2-6 weeks to build effect. Don't give up after 1 week - give it adequate time.
Can I stop taking non-stimulants on weekends like I can with stimulants?
No. Non-stimulants must be taken daily for continuous effect. Stopping them results in loss of benefit. Alpha-2 agonists (Intuniv, Kapvay) must be tapered - stopping abruptly can cause dangerous rebound hypertension.
Are non-stimulants less addictive?
Yes. Non-stimulants (except Qelbree) are not controlled substances and have minimal to no abuse potential. This makes them safer for patients with substance use history or in situations where diversion is a concern (college, adolescents).
🔬 About Dr. Ryan Sultan
Dr. Ryan Sultan is an Assistant Professor of Clinical Psychiatry at Columbia University and a leading ADHD researcher. His 2019 JAMA study on ADHD medications has been cited 440+ times and informed FDA policy on ADHD treatment.
Dr. Sultan's ADHD Medication Expertise:
- 15+ years prescribing and researching ADHD medications
- $670K+ in NIH funding for ADHD pharmacotherapy research
- 50+ publications on stimulant and non-stimulant ADHD treatments
- Double board-certified: Adult Psychiatry & Child/Adolescent Psychiatry
- Treats ADHD across the lifespan (children, adolescents, adults)
Learn more about Dr. Sultan's ADHD expertise →